The 20th annual edition of the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for prostate cancer has been published. The new guidelines include major changes on use of imaging, including the use of multiparametric MRI for the risk stratification of men on active surveillance and use of PET for bone scans. New guidance on molecular testing and the systemic treatment of castration-resistant prostate cancer are also included.
References
National Comprehensive Cancer Network. Changing the course of prostate cancer treatment: life expectancy estimation, active surveillance, and drug development. National Comprehensive Cancer Network [online], (2014)
Rights and permissions
About this article
Cite this article
NCCN guidelines for prostate cancer updated. Nat Rev Urol 12, 63 (2015). https://doi.org/10.1038/nrurol.2014.350
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.350
This article is cited by
-
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
Prostate Cancer and Prostatic Diseases (2019)
-
The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients
Prostate Cancer and Prostatic Diseases (2017)